Liu Shi Xin

Nueva
40 años de experiencia
Ubicación: China, Xiamen
Clínica:Hospital Xiamen Humanity
El profesor Shixin Liu, MD, PhD, es el líder de la disciplina del Centro de Oncología. Fue presidente del Hospital Oncológico Provincial de Jilin y director del Instituto de Investigación en Prevención y Tratamiento del Cáncer. Es profesor de nivel II y tutor de doctorado. Ha recibido la Asignación Especial del Gobierno del Consejo de Estado, el 4.º premio Médico Nacional Famoso (Contribución Sobresaliente) y la distinción Modelo de Ética Médica.

Se especializa en el diagnóstico y tratamiento integrales de tumores malignos. Su enfoque es la radioterapia de precisión para cánceres torácicos y abdominales. Domina IMRT, VMAT y SBRT para cáncer de pulmón, esófago, mama y recto.

Sus cargos de liderazgo incluyen la vicepresidencia de Oncología Radioterápica de la CMA, de Radioterapia de la CACA y de Terapia de Partículas de la CACA. Integra el Comité Permanente de la CSCO y es vicepresidente del Comité de Expertos en Oncología Radioterápica de la CSCO. Es vicepresidente de Oncología Radioterápica de la CPAM y miembro del Comité Permanente de la CSMEA. Preside la sección de Oncología Radioterápica de la Asociación Médica de Jilin. Forma parte de los consejos editoriales del Chinese Journal of Radiation Oncology y del Practical Journal of Cancer.
Mostrar más

Nueva

Cita con el médico

Precio a consultar

Bookimed Insights: Principales especialistas en Cancer de RIÑON en China (2026)

Bookimed ha coordinado 53707 solicitudes para el tratamiento de Cancer de RIÑON en China, colaborando con 1 especialistas de primer nivel. Los médicos en esta tabla se seleccionan por sus credenciales internacionales, experiencia clínica y resultados de pacientes. La clasificación de 2026 se elabora con datos verificados de casos reales y programas actuales de nuestras clínicas asociadas.

Clasificación	Médico	experiencia	Buena opción para	Qué los distingue	Ubicación de la clínica	Consulta

FAQ

Estas preguntas frecuentes provienen de pacientes reales que buscan atención médica a través de Bookimed. Las respuestas son proporcionadas por coordinadores médicos experimentados y representantes autorizados de las clínicas.

What are the main kidney-cancer treatment options available in leading Chinese hospitals?

Leading Chinese hospitals treat kidney cancer using robotic-assisted nephrectomy, cryosurgery, and targeted therapies. Specialized centers combine minimally invasive surgery with advanced ablation for small tumors. High-volume academic institutions utilize the da Vinci system for precise, nephron-sparing procedures. These methods aim to preserve healthy kidney tissue.

Surgical techniques: Partial or radical nephrectomy performed via laparoscopic or robotic-assisted methods.
Ablation therapy: Cryosurgery and NanoKnife treat small tumors in patients avoiding major surgery.
Radiation oncology: Precise CyberKnife M6 and proton-beam therapy target tumors while sparing organs.
Systemic treatment: Targeted drugs and immunotherapy combinations manage advanced or metastatic renal cancer.

Bookimed Expert Insight: China is a global leader in cryosurgery for kidney cancer. Professor Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries. This procedure is often used for tumors smaller than 4 cm. It offers a safe alternative for elderly patients. The hospital is JCI-accredited and treats patients from over 100 countries. Specialist experience at this volume is rare in many other regions.

Patient Consensus: Patients note that robotic surgery allows for a quick recovery and usually avoids blood transfusions. Many emphasize the importance of using WeChat groups to find real-time tips for navigating large hospitals.

Are Chinese kidney-cancer centers safe and how do their clinical outcomes compare internationally?

Major Chinese kidney cancer centers are safe and offer specialized care at international quality levels. Top-tier institutions like Fuda Cancer Hospital hold JCI accreditation. National data shows 5-year survival rates for renal cell carcinoma reaching 69.8%. These figures now closely track performance in high-income western nations.

Success rates: Survival indices in China have surpassed global averages since 2010.
Specialized technology: Centers utilize NanoKnife, CyberKnife M6, and Da Vinci robotic systems.
High volume: Dr. Niu Lizhi has performed over 10,000 cryosurgery procedures personally.
Clinical quality: National standards for renal cancer ensure uniform diagnostic and treatment protocols.

Bookimed Expert Insight: While general survival rates are high, the true value in China lies in specialized cryosurgery and NanoKnife technology for advanced cases. Fuda Cancer Hospital treats over 30,000 international patients annually. This massive volume allows surgeons to maintain expertise in complex, minimally invasive techniques that may be less common elsewhere. For example, Dr. Niu Lizhi treats a vast age range from 4 to 94 years old. This suggests a high level of technical adaptability for high-risk patients.

Patient Consensus: Patients note that top-tier hospitals provide excellent technical outcomes and advanced surgical technology. They suggest hiring a translator to help manage side effects and clarify follow-up instructions during recovery.

Which hospitals in China are most experienced in treating international kidney-cancer patients?

Fuda Cancer Hospital in Guangzhou and Beijing United Family Hospital are among Chinas most experienced facilities for international kidney cancer patients. These JCI-accredited centers specialize in minimally invasive technologies. They offer advanced cryosurgery, NanoKnife therapy, and robotic nephrectomy for complex or late-stage cases.

Patient volume: Fuda Cancer Hospital has treated over 30,000 patients from 100+ different countries.
Advanced technology: Facilities utilize the Da Vinci Robot and CyberKnife M6 for precise tumor removal.
Specialized expertise: Dr. Niu Lizhi has performed nearly 10,000 cryosurgery and 500 NanoKnife procedures.
International standards: Jiahui International Hospital maintains a formal clinical partnership with Massachusetts General Hospital.

Bookimed Expert Insight: While many seek robotic surgery, Chinas specific advantage in kidney cancer lies in non-surgical ablation. Fuda Cancer Hospital provides over 10 types of minimally invasive therapies. Dr. Niu Lizhi is a global authority in cryosurgery. This makes these clinics a primary choice for patients with tumors in difficult locations.

Patient Consensus: Patients often favor major cities like Beijing and Shanghai for metastatic cases. They note that English-speaking staff and JCI accreditation at private international hospitals ensure much smoother medical journeys.

What does recovery and follow-up look like after kidney-cancer surgery or ablation in China?

Recovery after kidney cancer surgery in China typically requires 3 to 5 days of hospitalization. Minimally invasive procedures like cryoablation or NanoKnife often allow for discharge within 48 hours. Follow-up protocols include abdominal CT or MRI every 3 to 6 months during the first 2 years.

Hospital stay: Expect 3 to 5 days for laparoscopic or robotic nephrectomy.
Physical activity: Avoid lifting over 10kg for at least 4 to 6 weeks.
Ablation side effects: Mild fever or nausea may last up to 10 days post-procedure.
Surveillance tools: Contrast-enhanced CT remains the gold standard for monitoring local recurrence.

Bookimed Expert Insight: Clinical volume significantly impacts expertise in specialized treatments like cryosurgery. Professor Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries personally. This high procedural volume at JCI-accredited centers often leads to more refined recovery protocols for complex late-stage cases.

Patient Consensus: Patients note that while physical recovery from ablation is fast, adhering to the 6-week lifting restriction is vital to prevent internal bleeding. Many also suggest using translation apps to navigate medical documents, as getting English-language scan reports can be challenging.

Who is a good candidate for minimally invasive ablative procedures rather than open surgery in China?

Ideal candidates for minimally invasive ablation in China include patients with small kidney tumors under 4 cm (stage T1a). This approach suits individuals with high surgical risks due to age or heart disease. It specifically benefits those needing to preserve renal function or managing a solitary kidney.

Tumor size: Most effective for localized lesions smaller than 3 to 4 cm.
Medical comorbidities: Preferred for patients with poor heart, lung, or liver function.
Organ preservation: Critical for patients with one kidney to avoid lifelong dialysis.
Nonsurgical status: Safe alternative for those ineligible for general anesthesia or major trauma.

Bookimed Expert Insight: While many overlook specialized oncology centers, Fuda Cancer Hospital in Guangzhou provides a distinct advantage with over 10,000 cryosurgeries performed. Professor Niu Lizhi has personally completed 500 NanoKnife procedures, which is a rare expertise level globally. Patients should prioritize these high-volume centers, as specialized experience with NanoKnife and cryoablation often leads to better preservation of healthy kidney tissue than generalized surgical departments.

Patient Consensus: Patients note that ablation offers a much faster recovery with minimal scarring compared to open surgery. Many emphasize that while it carries a slightly higher recurrence risk, the benefit of keeping 80% of kidney function makes it the preferred choice for early-stage cases.

What is `Integrative Oncology` and how is it applied to kidney-cancer care in China?

Integrative oncology in China is a patient-centered field combining conventional medical treatments with evidence-informed complementary therapies. This integrated Chinese and Western medicine model uses technologies like the Da Vinci Robot or CyberKnife M6 alongside traditional practices to manage symptoms and improve quality of life.

Symptom management: Acupuncture and herbal decoctions alleviate nausea, fatigue, and neuropathy from immunotherapy.
Immune support: Herbal formulas combined with interferon treatments help increase essential immune cell counts.
Targeted formulations: Formulas like Bu-Shen-Jian-Pi-Fang aim to inhibit tumor growth and prevent metastasis.
Recovery protocols: Post-surgical care integrates dietary management and movement practices to promote renal function.

Bookimed Expert Insight: Our data highlights that top Chinese centers often replace aggressive chemotherapy with over 10 types of minimally invasive therapies. For instance, Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries for advanced stages. These clinics often hold JCI accreditation, ensuring that traditional integrations meet rigorous international safety standards. Patients seeking this approach should prioritize hospitals with high international patient volumes, such as those serving 30,000+ people from 100 countries.

Patient Consensus: Patients note that combining partial nephrectomy with specific herbs helps strengthen their energy and may stabilize tumors before surgery. Many emphasize the importance of using monitored medical teams to ensure herbs do not interfere with standard kidney function.

Which Chinese cities are well equipped for medical tourists seeking kidney-cancer treatment?

Guangzhou, Beijing, and Shanghai are China's primary hubs for advanced kidney cancer treatment. These cities host JCI-accredited facilities specializing in minimally invasive oncology. International patients often access cryosurgery, NanoKnife ablation, and robotic-assisted nephrectomy. Specialized centers in these regions offer multidisciplinary care for complex renal cases.

Guangzhou oncology: Fuda Cancer Hospital provides cryosurgery and NanoKnife for advanced tumors.
Beijing expertise: Facilities like Peking Union offer proton therapy and CyberKnife technology.
Shanghai technology: Fudan University Shanghai Cancer Center specializes in heavy ion radiotherapy.
Treatment range: Options include laparoscopic nephrectomy, immunotherapy, and Da Vinci robotic surgery.
Patient capacity: Guangzhou's Fuda Hospital has treated over 30,000 international oncology patients.

Bookimed Expert Insight: Guangzhou stands out for specialized experience in late-stage renal cases. Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries. This high volume often allows for treating patients aged 4 to 94. While Shanghai and Beijing offer traditional excellence, Guangzhou's focus on non-invasive ablation makes it a focal point for those seeking alternatives to standard surgery.

Patient Consensus: Patients note that Shanghai and Beijing offer world-class urology technology. Many emphasize hiring a local translator or fixer to manage visa paperwork and post-operative care communication.

Los mejores médicos del tratamiento de Cancer de RIÑON en Xiamen - TOP-1 médicos

Recibe cotizaciones de 3 de los mejores especialistas en en China